Feb 10 (Reuters) - Indian drugmaker Lupin ‌said on Tuesday it ‌agreed to a $90 million settlement with Japan's Astellas Pharma in a patent dispute over the bladder ‍disorder drug Mirabegron, a move ...

USD 90 million, which includes a Prepaid Option Payment of USD 75 million, and (2) a Prepaid Per Unit License Fee for each unit of Lupin Product sold from the date of the settlement through September ...

Feb 10 (Reuters) - Indian drugmaker Lupin said on Tuesday it has settled a patent infringement dispute with Japan's Astellas Pharma over the bladder disorder drug Mirabegron, allowing it to continue ...

Feb 12 (Reuters) - India's Zydus Lifesciences and its U.S. unit will pay $120 million ‌to Astellas Pharma as part of ‌a deal to settle a patent dispute over the Japanese drugmaker's bladder disorder ...

Feb 12 (Reuters) - India's Zydus Lifesciences said on Thursday that it and its U.S. unit have agreed to pay $120 million to Astellas Pharma as part of a deal to settle a patent dispute over the ...

FILE PHOTO: The logo of Lupin, India's No. 2 drugmaker, is seen on the facade of its pharmaceutical plant in Verna FILE PHOTO: The logo of Lupin, India's No. 2 drugmaker, is seen on the facade of its ...

Paramount to buy Warner Bros Discovery in $110 billion deal as Netflix bows out of race Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, ...